VALBIOTIS news, videos and press releases
For more news please use our advanced search feature.
VALBIOTIS - More news...
VALBIOTIS - More news...
- VALBIOTIS SA: Valbiotis® strengthens its foothold in pharmacies with two strategic partnerships
- VALBIOTIS SA: In anticipation of a change in regulations, Valbiotis® offers a scientifically proven alternative to red yeast rice for cholesterol management
- VALBIOTIS SA: Valbiotis unveils its annual financial statements and confirms its strategic and financial goals
- VALBIOTIS SA: Valbiotis to launch its solution for the prevention of metabolic diseases, Valbiotis®PRO Metabolic Health (Totum•63), on February 3rd
- VALBIOTIS SA: Valbiotis unveils its strategic and financial goals for 2030
- VALBIOTIS SA: Valbiotis announces the major success of the phase II/III HEART II clinical study on LIPIDRIVE
- VALBIOTIS SA: Valbiotis® announces a strategic partnership with Asetys, a complementary health insurance provider and recognized specialist in natural solutions and prevention
- VALBIOTIS to launch Valbiotis®PRO Metabolic Health (Totum•63) for the prevention of metabolic diseases on the French market in February-March 2025.
- VALBIOTIS publishes its interim financial statements
- Valbiotis announces the major success of the INSIGHT clinical study on TOTUM•854
- VALBIOTIS : Oral presentation at the 2024 EASD congress
- Valbiotis invited to present clinical results at the American Diabetes Association’s 84th Scientific Sessions
- Valbiotis reaches an agreement to terminate its licensing and supply agreement with Nestlé Health Science
- Valbiotis launches its e-commerce site for the marketing of Valbiotis®PRO Cholestérol
- Valbiotis publishes its annual accounts 2023
- Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May
- Valbiotis presents its 2024 financial communication calendar
- Valbiotis sets out its commercial and clinical roadmap for 2024
- Valbiotis announces the success of its €15 M capital increase
- Valbiotis announces the launch of a capital increase
- Valbiotis announces the availability of an amendment to the Universal Registration Document
- Valbiotis announces that it has received Food and Drug Administration (FDA) approval for New Dietary Ingredient (NDI) status
- VALBIOTIS SA:
- Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes
- VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes
- Valbiotis publishes its financial report for the first half of 2023 and confirms its strategic roadmap
- VALBIOTIS SA: Valbiotis presents the full results of the Phase II/III REVERSE-IT study: impressive efficacy of TOTUM•63 against prediabetes and the early stages of type 2 diabetes
- VALBIOTIS SA: Valbiotis Presents the Full Results of the Phase II/III REVERSE-IT Study: Impressive Efficacy of TOTUM•63 Against Prediabetes and the Early Stages of Type 2 Diabetes, a First for a Non-drug Active Substance
- Valbiotis announces its roadmap and strategic priorities on the eve of key milestones for its portfolio of innovative active substances
- Valbiotis announces the appointment of Charlotte JEZEQUEL as Director of Human Relations and Executive Committee member
